• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于入院特征的原发性肝切除术后合并糖尿病的早期肝细胞癌列线图预后模型

A nomogram prognostic model for early hepatocellular carcinoma with diabetes mellitus after primary liver resection based on the admission characteristics.

作者信息

Zhang Menghan, Wang Qi, Zhang Gongming, Li Guangming, Jin Ronghua, Xing Huichun

机构信息

Center of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing, China.

Beijing Ditan Hospital, Capital Medical University, Beijing, China.

出版信息

Front Pharmacol. 2024 Feb 15;15:1360478. doi: 10.3389/fphar.2024.1360478. eCollection 2024.

DOI:10.3389/fphar.2024.1360478
PMID:38434702
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10905961/
Abstract

Patients diagnosed with early-stage hepatocellular carcinoma (HCC) and diabetes mellitus (DM) are at a higher risk of experiencing complications and facing increased mortality rates. Hence, it is crucial to develop personalized clinical strategies for this particular subgroup upon their admission. The objective of this study is to determine the key prognostic factors in early HCC patients who received liver resection combined with DM and develop a practical personalized model for precise prediction of overall survival in these individuals. A total of 1496 patients diagnosed hepatitis B virus (HBV) - related liver cancer from Beijing You'an Hospital were retrospectively enrolled, spanning from 1 January 2014, to 31 December 2019, and ultimately, 622 eligible patients of hepatocellular carcinoma (HCC) patients with diabetes were included in this present investigation. A multivariate COX regression analysis was conducted to identify prognostic factors that are independent of each other and develop a nomogram. The performance of the nomogram was evaluated using various statistical measures such as the C-index, receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA) in both the training and validation groups. Survival rates were estimated using the Kaplan-Meier method. The study included a total of 622 early HCC patients who underwent liver resection combined with DM. Random Forrest model and Multivariate Cox regression analysis revealed that drinking, tumor number, monocyte-to-lymphocyte ratio, white blood cell count and international normalized ratio at admission were identified as independent prognostic factors for early HCC patients who underwent liver resection combined with DM. The nomogram demonstrated good predictive performance in the training and validation cohorts based on the C-index values of 0 .756 and 0 .739 respectively, as well as the area under the curve values for 3-, 5-, and 8-year overall survival (0.797, 0.807, 0.840, and 0.725, 0.791, 0.855). Calibration curves and decision curve analysis indicated high accuracy and net clinical benefit rates. Furthermore, the nomogram successfully stratified enrolled patients into low-risk and high-risk groups based on their risk of overall survival. The difference in overall survival between these two groups was statistically significant in both the training and validation cohorts ( < 0.0001 and = 0.0064). Our results indicate that the admission characteristics demonstrate a highly effective ability to predict the overall survival of early HCC patients who have undergone liver resection in combination with DM. The developed model has the potential to support healthcare professionals in making more informed initial clinical judgments for this particular subgroup of patients.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23be/10905961/7c56d8f500f9/fphar-15-1360478-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23be/10905961/bb99cc49691a/fphar-15-1360478-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23be/10905961/a0a1c0291559/fphar-15-1360478-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23be/10905961/ecdb36001363/fphar-15-1360478-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23be/10905961/49910d942941/fphar-15-1360478-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23be/10905961/0c68229923f8/fphar-15-1360478-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23be/10905961/7c56d8f500f9/fphar-15-1360478-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23be/10905961/bb99cc49691a/fphar-15-1360478-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23be/10905961/a0a1c0291559/fphar-15-1360478-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23be/10905961/ecdb36001363/fphar-15-1360478-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23be/10905961/49910d942941/fphar-15-1360478-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23be/10905961/0c68229923f8/fphar-15-1360478-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23be/10905961/7c56d8f500f9/fphar-15-1360478-g006.jpg

被诊断为早期肝细胞癌(HCC)和糖尿病(DM)的患者发生并发症和面临更高死亡率的风险更高。因此,针对这一特定亚组患者入院时制定个性化临床策略至关重要。本研究的目的是确定接受肝切除联合糖尿病治疗的早期肝癌患者的关键预后因素,并建立一个实用的个性化模型,以精确预测这些患者的总生存期。本研究回顾性纳入了1496例来自北京佑安医院诊断为乙型肝炎病毒(HBV)相关肝癌的患者,时间跨度从2014年1月1日至2019年12月31日,最终,622例符合条件的肝细胞癌(HCC)合并糖尿病患者被纳入本研究。进行多因素COX回归分析以识别相互独立的预后因素并绘制列线图。在训练组和验证组中,使用各种统计方法(如C指数、受试者工作特征曲线(ROC)、校准曲线和决策曲线分析(DCA))评估列线图的性能。采用Kaplan-Meier法估计生存率。本研究共纳入622例接受肝切除联合糖尿病治疗的早期肝癌患者。随机森林模型和多因素COX回归分析显示,饮酒、肿瘤数量、单核细胞与淋巴细胞比值、入院时白细胞计数和国际标准化比值被确定为接受肝切除联合糖尿病治疗的早期肝癌患者的独立预后因素。基于C指数值分别为0.756和0.739,以及3年、5年和8年总生存期的曲线下面积值(0.797、0.807、0.840和0.725、0.791、0.855),列线图在训练组和验证组中均显示出良好的预测性能。校准曲线和决策曲线分析表明具有较高的准确性和净临床获益率。此外,列线图成功地根据总生存风险将纳入的患者分为低风险和高风险组。在训练组和验证组中,这两组患者的总生存期差异均具有统计学意义(<0.0001和=0.0064)。我们的结果表明,入院特征对预测接受肝切除联合糖尿病治疗的早期肝癌患者的总生存期具有高效能。所建立的模型有可能支持医疗保健专业人员对这一特定亚组患者做出更明智的初始临床判断。

相似文献

1
A nomogram prognostic model for early hepatocellular carcinoma with diabetes mellitus after primary liver resection based on the admission characteristics.基于入院特征的原发性肝切除术后合并糖尿病的早期肝细胞癌列线图预后模型
Front Pharmacol. 2024 Feb 15;15:1360478. doi: 10.3389/fphar.2024.1360478. eCollection 2024.
2
Prognostic model for predicting recurrence in hepatocellular carcinoma patients with high systemic immune-inflammation index based on machine learning in a multicenter study.基于多中心研究的机器学习构建高全身免疫炎症指数肝癌患者复发预测的预后模型。
Front Immunol. 2024 Sep 9;15:1459740. doi: 10.3389/fimmu.2024.1459740. eCollection 2024.
3
Construction and validation of a machine learning-based nomogram to predict the prognosis of HBV associated hepatocellular carcinoma patients with high levels of hepatitis B surface antigen in primary local treatment: a multicenter study.基于机器学习的列线图构建与验证:预测初治时高乙型肝炎表面抗原水平的乙型肝炎病毒相关肝细胞癌患者的预后:一项多中心研究。
Front Immunol. 2024 Mar 27;15:1357496. doi: 10.3389/fimmu.2024.1357496. eCollection 2024.
4
Machine learning-based model for predicting tumor recurrence after interventional therapy in HBV-related hepatocellular carcinoma patients with low preoperative platelet-albumin-bilirubin score.基于机器学习的模型,用于预测术前血小板-白蛋白-胆红素评分低的 HBV 相关肝细胞癌患者介入治疗后肿瘤复发。
Front Immunol. 2024 May 28;15:1409443. doi: 10.3389/fimmu.2024.1409443. eCollection 2024.
5
Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma.基于术前增强 CT 的影像组学模型预测肝细胞癌患者总生存期。
World J Gastroenterol. 2022 Aug 21;28(31):4376-4389. doi: 10.3748/wjg.v28.i31.4376.
6
Prognostic nomogram based on the gamma-glutamyl transpeptidase-to-platelet ratio for patients with compensated cirrhotic hepatocellular carcinoma after local ablation.基于γ-谷氨酰转肽酶与血小板比值的预后列线图在局部消融后代偿期肝硬化肝细胞癌患者中的应用
Front Oncol. 2024 Jul 11;14:1406764. doi: 10.3389/fonc.2024.1406764. eCollection 2024.
7
A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma.一种预测肝细胞癌无复发生存率和总生存率的新型列线图模型。
Front Oncol. 2022 Jul 22;12:946531. doi: 10.3389/fonc.2022.946531. eCollection 2022.
8
Development and validation of nomogram to predict overall survival and disease-free survival after surgical resection in elderly patients with hepatocellular carcinoma.预测老年肝细胞癌患者手术切除后总生存期和无病生存期的列线图的开发与验证
Front Oncol. 2024 May 24;14:1395740. doi: 10.3389/fonc.2024.1395740. eCollection 2024.
9
Development and validation of a prognostic nomogram to predict the recurrence of AFP-negative and DCP-positive hepatocellular carcinoma after curative resection.用于预测根治性切除术后甲胎蛋白阴性且异常凝血酶原阳性肝细胞癌复发的预后列线图的开发与验证
Front Oncol. 2024 Aug 8;14:1414083. doi: 10.3389/fonc.2024.1414083. eCollection 2024.
10
Development and validation of a nomogram to predict the recurrence of hepatocellular carcinoma patients with dynamic changes in AFP undergoing locoregional treatments.用于预测接受局部区域治疗且甲胎蛋白动态变化的肝细胞癌患者复发的列线图的开发与验证。
Front Oncol. 2023 Aug 28;13:1206345. doi: 10.3389/fonc.2023.1206345. eCollection 2023.

本文引用的文献

1
Development and validation of a prediction tool for intraoperative blood transfusion in brain tumor resection surgery: a retrospective analysis.开发和验证用于脑肿瘤切除术术中输血预测的工具:回顾性分析。
Sci Rep. 2023 Oct 13;13(1):17428. doi: 10.1038/s41598-023-44549-x.
2
Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa region.中东和北非地区肝细胞癌管理的多学科共识建议。
Liver Int. 2023 Oct;43(10):2062-2077. doi: 10.1111/liv.15685. Epub 2023 Aug 8.
3
Prothrombin time (PT) and CEA as prognostic predictive biomarkers for postoperative recurrence after curative resection in patients with stage I-III colorectal cancer: a retrospective cohort study.
凝血酶原时间(PT)和癌胚抗原(CEA)作为 I-III 期结直肠癌患者根治性切除术后术后复发的预后预测生物标志物:一项回顾性队列研究。
Updates Surg. 2022 Jun;74(3):999-1009. doi: 10.1007/s13304-022-01268-8. Epub 2022 Mar 24.
4
The monocyte to lymphocyte ratio not only at baseline but also at relapse predicts poor outcomes in patients with hepatocellular carcinoma receiving locoregional therapy.单核细胞与淋巴细胞比值不仅在基线时,而且在复发时,均可预测接受局部区域治疗的肝细胞癌患者的不良结局。
BMC Gastroenterol. 2022 Mar 4;22(1):98. doi: 10.1186/s12876-022-02180-6.
5
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2022.2. 糖尿病的分类和诊断:2022 年糖尿病医疗护理标准。
Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38. doi: 10.2337/dc22-S002.
6
Development and Validation of a Practical Prognostic Coagulation Index for Patients with Esophageal Squamous Cell Cancer.开发和验证一种用于食管鳞癌患者的实用预后凝血指数。
Ann Surg Oncol. 2021 Dec;28(13):8450-8461. doi: 10.1245/s10434-021-10239-z. Epub 2021 Jun 8.
7
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.非酒精性脂肪性肝病与 2 型糖尿病之间的复杂关系——机制与治疗。
Nat Rev Gastroenterol Hepatol. 2021 Sep;18(9):599-612. doi: 10.1038/s41575-021-00448-y. Epub 2021 May 10.
8
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
9
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
10
Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.分子机制:非酒精性脂肪性肝病、脂肪性肝炎和肝细胞癌之间的联系。
Int J Mol Sci. 2020 Feb 23;21(4):1525. doi: 10.3390/ijms21041525.